DEF: Abpro Holdings Seeks Reverse Stock Split to Maintain Nasdaq Listing

Abpro Holdings, Inc. will hold its Annual Meeting on September 18, 2025, to vote on the re-election of a director, ratification of its auditor, and a critical one-for-ten reverse stock split aimed at regaining Nasdaq compliance.

Summary

• The Annual Meeting of Stockholders will be held virtually on Thursday, September 18, 2025, at 10:00 a.m. Eastern Time.
• Stockholders will vote on three proposals: re-electing one Class I director (Ian McDonald), ratifying Wolf & Company, P.C. as the independent registered public accounting firm for fiscal year 2025, and approving a one-for-ten reverse stock split.
• The proposed reverse stock split is a direct response to a Nasdaq Minimum Bid Price Notice received on April 2, 2025, as the company's common stock no longer complies with the $1.00 minimum bid price requirement.
• As of the record date, September 2, 2025, there were 80,166,667 shares of common stock outstanding, with a closing bid price of $0.252 per share.
• If implemented, the reverse stock split would reduce the number of outstanding shares to approximately 8,016,667 and is expected to increase the per-share price to an estimated $2.52.
• The company completed a Business Combination with Atlantic Coastal Acquisition Corp. II (ACAB) on November 13, 2024, and subsequently changed its name to Abpro Holdings, Inc.
• Wolf & Company, P.C. was appointed as the independent registered public accounting firm on December 9, 2024, replacing Marcum LLP (now CBIZ CPAs P.C.).
• Consolidated financial statements for periods ended September 30, 2024, December 31, 2023, and December 31, 2022, were restated to correct accrued expenses, total liabilities, and accumulated deficit balances.

Sentiment

Score: 3

Explanation: The company is taking necessary steps to address a critical Nasdaq listing issue, but the underlying financial and operational challenges (low stock price, restatements, going concern doubt, internal control weaknesses) indicate significant headwinds and a high-risk profile.

Positives

• The Board unanimously recommends all proposals, including the reverse stock split, indicating internal alignment on strategic direction.
• The proposed reverse stock split is a proactive measure to maintain Nasdaq listing, which is crucial for market access, liquidity, and investor confidence.
• The company has established robust corporate governance structures, including independent Audit, Compensation, and Nominating and Corporate Governance Committees, with all members qualifying as independent directors.
• The adoption of a Clawback Policy in October 2023 demonstrates a commitment to executive accountability and compliance with SEC regulations.
• The appointment of Wolf & Company, P.C. as the new independent auditor is a standard practice post-business combination, aiming to ensure appropriate financial oversight.

Negatives

• The company received a Nasdaq Minimum Bid Price Notice on April 2, 2025, indicating non-compliance with the $1.00 minimum bid price requirement, signaling significant stock price underperformance.
• Consolidated financial statements for multiple periods (September 30, 2024, December 31, 2023, and December 31, 2022) were restated due to corrected accrued expenses, total liabilities, and accumulated deficit balances.
• Marcum LLP, the previous independent auditor, expressed 'substantial doubt' regarding the company's ability to continue as a going concern in its audit reports for 2023 and 2022.
• Material weaknesses in internal control over financial reporting were identified by ACAB prior to the Business Combination, including issues with timely tax filings, use of trust account cash for operating tax obligations, and over-accrual of expenses.
• Ian Chan and J. Wook (Miles) Suk, key executives, do not qualify as independent directors, which could raise concerns about board independence.
• One Form 3 and one Form 4 were filed late for Ian Chan in 2024, indicating potential issues with Section 16(a) compliance.

Risks

• There is no assurance that the proposed reverse stock split will increase the price of common stock or maintain compliance with Nasdaq's Minimum Bid Price Requirement.
• The market price per post-reverse stock split share may not exceed or remain in excess of the $1.00 minimum bid price for a sustained period, potentially leading to future delisting threats.
• The reverse stock split may not result in a per-share price or market capitalization that attracts brokers and institutional investors who typically avoid lower-priced stocks.
• The market price of common stock may decrease due to factors unrelated to the reverse stock split, and a post-split decline could represent a greater percentage loss.
• Even if the minimum bid price is met, the company may still be delisted if it fails to meet other Nasdaq listing requirements, such as minimum stockholders' equity or public float.
• The reverse stock split will increase the proportion of authorized but unused shares, which could lead to dilution for existing shareholders if additional shares are issued without further stockholder action.
• The company faces cybersecurity risks, which are overseen by the Audit Committee, and could impact operations and data security.

Future Outlook

The Board expects the reverse stock split to increase the market price of common stock, thereby maintaining Nasdaq compliance, improving marketability and liquidity, and potentially attracting a broader range of institutional investors and analyst interest. However, there is no assurance that these desired effects will materialize or be sustained, as the market price will also depend on the company's future performance and other unrelated factors.

Management Comments

• The Board unanimously recommends that you vote FOR the election of Ian McDonald to the Board.
• The Board unanimously recommends that you vote FOR Proposal 2 [ratification of Wolf & Company, P.C.].
• The Board unanimously recommends that you vote FOR Proposal 3 [approval of Reverse Stock Split].
• Management and the Board have considered the potential harm to us and our stockholders should Nasdaq delist our common stock from trading.
• Our Board does not intend for this transaction to be the first step in a series of plans or proposals to effect a going private transaction.

Industry Context

The biopharmaceutical industry frequently sees smaller or emerging growth companies facing challenges like low stock prices and delisting risks, especially those in early development stages or with limited commercial products. Reverse stock splits are a common strategy employed by such companies to address minimum bid price requirements and maintain exchange listings, which are critical for access to capital and investor visibility in this capital-intensive sector. The company's collaboration with Celltrion Inc. and focus on drug development indicate its positioning within the biopharma R&D landscape, where sustained funding and market presence are paramount.

Comparison to Industry Standards

• The company's need for a reverse stock split due to a sub-$1.00 stock price is a common challenge for smaller biopharmaceutical companies, particularly those in early development stages or with limited commercial products, as they often trade at lower valuations until key clinical milestones or commercialization.
• The restatement of financial statements and identified material weaknesses in internal controls, including issues with tax filings and expense accruals, suggest a need for improved financial reporting rigor, which is a critical standard for public companies, especially post-Business Combination.
• The adoption of a Clawback Policy is in line with recent SEC mandates (Rule 10D-1) and industry best practices for corporate governance, demonstrating an effort to align with contemporary standards.
• The staggered board structure and independent director majority align with common corporate governance standards for publicly traded companies, although the non-independent status of the CEO and a former CEO on the board warrants attention.

Management Changes

Corporate Governance

Related Party Transactions

• The Sponsor (Atlantic Coastal Acquisition Management II LLC) purchased 7,187,500 Founder Shares for $25,000 in October 2021.
• The Sponsor purchased 13,850,000 private placement warrants for $13,850,000 in connection with the ACAB IPO.
• The Sponsor loaned ACAB up to $250,000 in October 2021, with $149,539 repaid in February 2022.
• ACAB issued unsecured promissory notes totaling $160,000 to the Sponsor in October and November 2023 for monthly extensions.
• The Sponsor entered into an expense advancement agreement with ACAB in May 2024, agreeing to advance up to $600,000, replacing previous promissory notes.
• At the Business Combination closing, $2,000,000 of Sponsor advances were converted into 600,601 shares of common stock.
• The Sponsor forfeited 966,442 shares of common stock at the Closing pursuant to the Sponsor Letter Agreement.
• Polar Multi-Strategy Master Fund provided a capital contribution of up to $360,000 to the Sponsor, receiving 360,000 shares of common stock.
• Abpro Bio International, Inc. (a greater than 5% beneficial owner) entered into a Collaboration and License Agreement with Abpro Corporation in January 2020, with potential milestone payments of approximately $540 million.
• Abpro Bio International, Inc. made a $30 million equity investment in Abpro Corporation (Series E Preferred Stock) in 2020.
• Abpro Bio International, Inc. purchased $8.0 million of Series F Redeemable Convertible Preferred Stock in 2022.
• Abpro Corporation issued a Promissory Note to Abpro Bio International, Inc. for up to $6 million in October 2023 for expenses and operating costs.
• Ian Chan (former CEO, director) received a Promissory Note for $176,625 from Abpro Corporation in December 2023.
• Eugene Chan (former Chairman of Abpro Corporation) received a Promissory Note for $123,638 from Abpro Corporation in December 2023.
• Abpro Corporation entered into a consulting agreement with NEM LLC, whose sole member is Eugene Chan, for an annual payment of $250,000, which was terminated in 2024.
• Ian Chan received a promissory note agreement for up to $2,158,000 in funding from Abpro Corporation in April 2024, satisfied by 600,000 shares of common stock and 850,000 warrants.
• Shahraab Ahmad (CEO of ACAB) provided a bridge loan of $103,000 to Abpro Corporation in August 2024.
• A severance payment of $221,000 was made to an executive on November 21, 2024.
• A payment of $574,000 was made to the Sponsor on December 24, 2024.

Stakeholder Impact

• **Shareholders**: Will experience a reduction in the number of shares held (1-for-10 reverse split) but proportionate ownership will remain the same. There is potential for increased stock price and liquidity, but also a risk of further price decline and dilution from increased authorized but unissued shares. Voting on the proposals is critical for their investment.
• **Employees**: Executive compensation arrangements are in place, and equity incentive plans are subject to adjustment post-split. The Clawback Policy applies to executive officers, impacting their incentive compensation.
• **Investors (institutional)**: The reverse stock split aims to make the stock more attractive to institutions with policies against low-priced stocks, potentially increasing trading volume and liquidity, which could broaden the investor base.
• **Creditors**: The restatement of financial statements and the 'going concern' doubt expressed by the former auditor could impact perceptions of the company's financial stability and creditworthiness.

Next Steps

• Stockholders are to vote on the re-election of a director, auditor ratification, and the reverse stock split at the Annual Meeting on September 18, 2025.
• Management reserves the right to implement the approved reverse stock split on or prior to the one-year anniversary of the Annual Meeting.
• The company must regain Nasdaq minimum bid price compliance by September 29, 2025, or seek an additional compliance period.
• Final voting results from the Annual Meeting will be reported on a Current Report on Form 8-K filed with the SEC within four business days.
• The Board or Compensation Committee will adjust the number of shares underlying outstanding equity awards and shares available for future grants under the 2024 Incentive Plan to reflect the effects of the reverse stock split.

Key Dates

Recommendation

The company is addressing a critical Nasdaq listing issue with a proposed reverse stock split, which is a necessary step to maintain market access and liquidity. However, the underlying challenges, including a significantly depressed stock price, recent financial restatements, identified material weaknesses in internal controls, and auditors expressing 'substantial doubt' about the company's ability to continue as a going concern, indicate significant operational and financial risks. While the reverse split might temporarily boost the share price, the long-term viability and growth prospects remain highly uncertain. Investors should hold existing positions to observe the effectiveness of the reverse split and the company's ability to address its fundamental financial and operational issues, but new investment is not recommended given the high risk and lack of clear positive catalysts beyond regulatory compliance.

Keywords

Abpro Holdings, Reverse Stock Split, Nasdaq Listing, Proxy Statement, Biopharmaceutical, Corporate Governance, SEC Filing, Stock Split, Delisting Risk, Audit Committee, Executive Compensation, Related Party Transactions, ABP